RGNT
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of earnings/EPS.
- Low debt levels
- P/B of 3.13 is high for a company with no earnings
- No P/E or P/S available due to zero revenue
Future value is entirely dependent on binary clinical/regulatory success.
- High analyst target price ($10.00)
- No evidence of revenue growth
- No earnings growth data
Historical price performance is overwhelmingly bearish.
- Consistent -61.7% decline over 1Y, 3Y, and 5Y periods
- Technical trend is 0/100
Liquidity is currently stable, but operational health is failing.
- Current Ratio 2.65
- Low Debt/Equity
- Piotroski F-Score 3/9 (Weak)
- ROA -107.53%
Company is in a pre-revenue/growth phase; dividends are not applicable.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for RGNT and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
RGNT
Regentis Biomaterials Ltd.
Primary
|
-61.7% | -61.7% | -61.7% | -61.7% | -4.3% | -7.1% |
|
ICU
SeaStar Medical Holding Corporation
Peer
|
-99.8% | -99.3% | -70.8% | -35.1% | +33.9% | -13.9% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
|
HKPD
Cellyan Biotechnology Co., Ltd
Peer
|
-77.9% | -77.9% | -40.8% | -47.7% | -1.0% | +9.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
RGNT
Regentis Biomaterials Ltd.
|
BEARISH | $14.86M | - | -% | -% | $2.87 | |
|
ICU
SeaStar Medical Holding Corporation
|
BEARISH | $14.82M | - | -295.2% | -% | $3.71 | Compare |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | Compare |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
|
HKPD
Cellyan Biotechnology Co., Ltd
|
BEARISH | $14.62M | - | -13.4% | -4.3% | $0.62 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
RGNT filed its Form 20-F annual report on February 24, 2026, providing a comprehensive disclosure of its yearly financial performance and operational results. While specific financial metrics and risk factors were not provided in the excerpts, the filing serves as the primary regulatory document for assessing the company's fiscal health and risk profile.
Past News Coverage
Recent headlines mentioning RGNT from our newsroom.